- Home
- GOSS vs LCNB Comparison
GOSS vs LCNB Comparison
Compare GOSS & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- LCNB
- Stock Information
- Founded
- GOSS 2015
- LCNB 1877
- Country
- GOSS United States
- LCNB United States
- Employees
- GOSS N/A
- LCNB N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- LCNB Major Banks
- Sector
- GOSS Health Care
- LCNB Finance
- Exchange
- GOSS Nasdaq
- LCNB Nasdaq
- Market Cap
- GOSS 203.3M
- LCNB 197.9M
- IPO Year
- GOSS 2019
- LCNB N/A
- Fundamental
- Price
- GOSS $1.11
- LCNB $14.74
- Analyst Decision
- GOSS Strong Buy
- LCNB
- Analyst Count
- GOSS 4
- LCNB 0
- Target Price
- GOSS $7.50
- LCNB N/A
- AVG Volume (30 Days)
- GOSS 1.5M
- LCNB 18.8K
- Earning Date
- GOSS 05-20-2025
- LCNB 04-22-2025
- Dividend Yield
- GOSS N/A
- LCNB 6.03%
- EPS Growth
- GOSS N/A
- LCNB 31.98
- EPS
- GOSS N/A
- LCNB 1.14
- Revenue
- GOSS $114,701,000.00
- LCNB $82,862,000.00
- Revenue This Year
- GOSS N/A
- LCNB N/A
- Revenue Next Year
- GOSS $172.31
- LCNB $7.44
- P/E Ratio
- GOSS N/A
- LCNB $12.76
- Revenue Growth
- GOSS N/A
- LCNB 18.71
- 52 Week Low
- GOSS $0.50
- LCNB $12.42
- 52 Week High
- GOSS $1.55
- LCNB $17.92
- Technical
- Relative Strength Index (RSI)
- GOSS 55.81
- LCNB 53.08
- Support Level
- GOSS $1.06
- LCNB $14.46
- Resistance Level
- GOSS $1.26
- LCNB $14.90
- Average True Range (ATR)
- GOSS 0.11
- LCNB 0.47
- MACD
- GOSS 0.03
- LCNB 0.04
- Stochastic Oscillator
- GOSS 67.95
- LCNB 69.81
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.